Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions

[1]  J. Moslehi,et al.  Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept , 2022, Journal for ImmunoTherapy of Cancer.

[2]  A. Cohen,et al.  18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis. , 2022, Archives of cardiovascular diseases.

[3]  J. Ge,et al.  Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment , 2021, Frontiers in Pharmacology.

[4]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Landsberg,et al.  Cardiac MRI Depicts Immune Checkpoint Inhibitor-induced Myocarditis: A Prospective Study. , 2021, Radiology.

[6]  M. Kerneis,et al.  Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. , 2021, JAMA cardiology.

[7]  J. Durand,et al.  Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy , 2021, European journal of heart failure.

[8]  J. Moslehi,et al.  Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis , 2021, medRxiv.

[9]  Jing Wang,et al.  A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. , 2020, Cancer discovery.

[10]  Douglas B. Johnson,et al.  Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. , 2020, Annual review of pharmacology and toxicology.

[11]  O. Fardel,et al.  Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease. , 2020, Biochemical pharmacology.

[12]  R. Sullivan,et al.  Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. , 2020, Circulation.

[13]  Douglas B. Johnson,et al.  Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. , 2019, The New England journal of medicine.

[14]  Marc P. Bonaca,et al.  Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. , 2018, The Lancet. Oncology.

[15]  R. Sullivan,et al.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[16]  G. Freund,et al.  IL-4-dependent CD86 expression requires JAK/STAT6 activation and is negatively regulated by PKCdelta. , 2004, Cellular signalling.